Europe Home Infusion Therapy Market Size & Forecast 2025–2033

The Europe Home Infusion Therapy Market is on a steady path of transformation as healthcare systems across the continent increasingly prioritize patient convenience, cost-efficiency, and advanced technology integration. According to Renub Research, the market is expected to reach US$ 21.85 billion by 2033, rising from US$ 13.08 billion in 2024, with a strong and consistent CAGR of 5.87% during 2025–2033. This growth is primarily driven by the rising prevalence of chronic and age-related diseases, continued pressure on Europe’s healthcare budgets, and a fast-paced transition toward home-based treatments supported by technological innovation.

Home infusion therapy involves administering medications, fluids, nutrients, or biologics intravenously or subcutaneously—but instead of a clinical setting, treatment takes place in the patient’s home. This approach not only eases pressure on overcrowded hospitals but also significantly enhances patient quality of life. Europe, with its aging population and focus on advanced health infrastructure, stands at the forefront of this shift.

Download Free Sample Report

Europe Home Infusion Therapy Market Outlook

Home infusion therapy is widely used for a variety of treatments, including antibiotics, antivirals, hydration therapy, chemotherapy, pain management, parenteral nutrition, and advanced biologics. With chronic disease cases increasing at a rapid pace and demand for non-hospital care mounting, home infusion is becoming a preferred alternative for both patients and healthcare providers.

Patients who require long-term IV therapy often face challenges commuting to hospitals multiple times a week. With home-based options, such burdens are significantly reduced. In addition, home environments reduce exposure to hospital-acquired infections and allow for a more personalized treatment approach—a feature particularly appealing to older adults and immunocompromised patients.

Key Growth Drivers for the Europe Home Infusion Therapy Market

1. Rising Incidence of Chronic and Age-Related Conditions

Europe has one of the world’s oldest populations, with chronic diseases forming the leading cause of mortality and long-term disability. The region sees exceptionally high rates of:

Cancer

Cardiovascular disease

Diabetes

Chronic respiratory disorders

Autoimmune diseases

In fact, chronic diseases account for 85% of deaths in the EU, and cancer is the leading cause of mortality under the age of 65.

A significant portion of these conditions require prolonged or recurring intravenous therapy—something that is far more practical and cost-effective when offered at home. As the elderly population grows and healthcare infrastructure strains under increasing patient loads, home infusion therapy emerges as an ideal solution to maintain continuity of care.

2. Cost Savings and Reduced Hospitalization

European countries are striving to reduce healthcare expenditures while maintaining high standards of treatment. Home infusion therapy directly supports this goal by significantly cutting down:

Hospital stays

Readmission rates

Costs associated with inpatient care

Exposure to hospital-associated infections

With EU pharmaceutical laws being restructured in 2023 and a centralized Health Technology Assessment system set to launch in 2025, the regulatory landscape is increasingly supportive of home-based therapies. Payers, including national insurance systems, are also pushing for decentralized care models that reduce pressure on acute-care facilities.

3. Technological Advancements and Telemonitoring Adoption

Rapid progress in medical technology is one of the strongest accelerators of the home infusion therapy market. Today’s infusion pumps are:

Portable

Lightweight

Digitally programmable

Equipped with wireless monitoring

Compatible with AI-enabled dosing tools

Remote monitoring has emerged as a powerful resource for clinicians, enabling real-time tracking of patient vitals, infusion flow rates, and therapy adherence.

Notably, in April 2022, JMS Co., Ltd.’s “JMS Tongue Pressure Measurement Device” received EU-MDR certification, reflecting the continent’s growing influx of advanced home-based medical equipment.

Technology not only improves treatment accuracy but also empowers patients and caregivers, making complex therapies more intuitive and safer to administer at home.

Challenges Restricting Market Growth

1. Uneven Reimbursement and Policy Differences

Europe’s healthcare landscape varies significantly from country to country. While nations like Germany and France offer well-developed home care reimbursement systems, others—particularly in Eastern Europe—lag behind. This inconsistency makes it difficult for international infusion service providers to implement standardized strategies across the region.

Reimbursement limitations also affect patient access, delaying adoption in countries where home infusion is not fully integrated into national healthcare frameworks.

2. Shortage of Skilled Healthcare Professionals

Although home infusion therapy enables patient independence, it still requires involvement from trained nurses, pharmacists, and home care specialists. Europe faces a substantial workforce shortage, especially in underserved rural communities.

This shortage leads to:

Delayed treatment initiation

Inefficient service coverage

Geographic disparities in care access

Addressing workforce gaps will be crucial to ensuring that home infusion therapy can scale sustainably across the continent.

Segment Analysis: Europe Home Infusion Therapy Market

1. Europe Home Infusion Pump Market

Infusion pumps are the backbone of home infusion therapy. Modern pumps offer high accuracy and safety through features such as programmable controls, alarms, and wireless connectivity. As chronic disease rates rise and more patients opt for home-based long-term treatment, the infusion pump market continues to expand rapidly.

2. Europe Home Infusion IV Cannulas Market

IV cannulas are essential for reliable vascular access. Demand is rising due to growth in IV antibiotic therapy, cancer treatment, and immune deficiency management. Manufacturers are developing improved safety cannulas to reduce complications such as infections or extravasation—especially important for home settings where professional supervision is limited.

3. Europe Anti-Infective Home Infusion Therapy Market

Anti-infectives remain one of the most widely used home infusion categories, covering conditions like:

Osteomyelitis

Cellulitis

Post-surgical infections

Severe bacterial complications

With antimicrobial resistance increasing, patients often require extended IV therapy—making home infusion a logical and cost-effective solution. Hospitals across Europe continue to transition eligible patients into home care pathways to free up beds and reduce inpatient costs.

4. Europe Chemotherapy Home Infusion Therapy Market

Home-based chemotherapy has gained significant momentum across Europe due to better oncology practices, advanced infusion pump technologies, and supportive regulatory frameworks. Countries like the UK and France are expanding pilot programs to incorporate home oncology treatment into national healthcare strategies.

Home chemotherapy reduces hospital exposure for immunocompromised patients and allows cancer treatment to be administered with greater emotional comfort.

Country-Level Insights

Germany

Germany is one of the most mature home infusion markets in Europe. Supported by strong healthcare infrastructure and reliable reimbursement policies, Germany excels in providing:

Highly skilled home care professionals

Advanced infusion technologies

Comprehensive chronic disease management pathways

Anti-infectives, pain management, and parenteral nutrition are among the most commonly administered therapies. Government investments in digital health and home care have further strengthened market prospects.

United Kingdom

The NHS is actively shifting more patients toward home-based care to reduce strain on hospitals. Home infusion therapy for antibiotics, chemotherapy, and hydration is growing steadily.

In May 2025, BD launched its BD neXus next-generation infusion pump suite in the UK and Ireland—ushering in a new wave of technology adoption that enhances medication safety and workflow efficiency.

Despite challenges with staffing shortages, the UK continues to make headway through public–private partnerships and increased home-care funding.

France

France boasts a well-established home-care ecosystem supported by a government-funded healthcare system. Anti-infectives, chemotherapy, and nutrition therapy are widely administered at home. Strong reimbursement, high patient awareness, and extensive collaboration between public hospitals and private infusion providers support steady market expansion.

Russia

Russia’s home infusion therapy market is evolving rapidly, fueled by efforts to decentralize healthcare and improve access in non-urban areas. While challenges persist—including regional disparities and workforce limitations—investment in modernizing healthcare infrastructure is expected to unlock long-term growth opportunities.

Market Segmentation Overview

Product Type

Infusion Pump

Intravenous Sets

IV Cannulas

Needleless Connectors

Application

Anti-Infective

Hydration Therapy

Chemotherapy

Enteral Nutrition

Parenteral Nutrition

Specialty Pharmaceuticals

Others

Country Coverage

France, Germany, Italy, Spain, United Kingdom, Belgium, Netherlands, Russia, Poland, Greece, Norway, Romania, Portugal, Rest of Europe

Key Players Covered (5 Viewpoints Each)

Overviews, Key Person, Recent Developments, SWOT Analysis, Revenue Analysis

Pfizer Inc.

Smith & Nephew plc

Terumo Corporation

Johnson & Johnson Services, Inc.

Becton, Dickinson and Company

Baxter International Inc.

ICU Medical

Eli Lilly and Company

Final Thoughts

Europe’s home infusion therapy market is entering a pivotal phase where healthcare innovation intersects with patient demand for convenient, effective, and technology-supported treatment options. The shift toward decentralized care is no longer a trend—it is becoming a structural transformation across European healthcare systems.

With rising chronic disease prevalence, financial pressures on hospitals, and advancements in infusion devices and telemonitoring, home infusion therapy is poised to become a cornerstone of Europe’s future healthcare model.

As nations enhance regulatory support and technology companies bring new smart infusion solutions to market, Europe is well-positioned to maintain steady growth through 2033 and beyond.